New study reveals how blood cancers outsmart BTK-targeted therapies

Scientists astatine Sylvester Comprehensive Cancer Center, portion of the University of Miami Miller School of Medicine, and collaborators person uncovered a uncommon familial mutation that enables immoderate humor cancers to evade some approved Bruton tyrosine kinase (BTK) inhibitors and newer BTK degraders, a uncovering that could assistance signifier the adjacent procreation of therapies for patients with chronic lymphocytic leukemia (CLL) and related malignancies.